Zhejiang Geyi Medical Instrument Co., Ltd. appears in the linked FDA records as the applicant for two traditional 510(k) clearances decided in 2026. One covers a single-use digital flexible ureteroscope under product code FGB; the other covers a single-use digital hysteroscope under product code HIH. Both records show a Substantially Equivalent decision and a Summary statement. The company's own website describes a manufacturing operation in Jiande, Hangzhou, China, and a line of single-use endoscopes. [1][2][5]
Ureteroscope clearance K262437
K262437 names the Single-use Digital Flexible Ureteroscope in models GY-UR6.3 and GY-UR6.3A. The FDA record lists product code FGB, regulation number 876.1500, device class 2, advisory committee Gastroenterology/Urology, a Traditional clearance type and a decision date of October 29, 2026, with the application received July 16, 2026. The decision is recorded as Substantially Equivalent. [1][9]
A separate FDA letter in the public documents addresses the same K262437 submission, identifying the trade name, regulation number 21 CFR 876.1500, regulatory class II and product code FGB. The company's product page for a 6.3Fr single-use ureteroscope lists a 275-degree bidirectional bending range, 1:1 coaxial steering, handle keys with up to 15 presettable functions, a front LED light source, a CMOS sensor and 160,000-pixel imaging. Those specifications are published by the company, not confirmed in the FDA record. [4][6]
Hysteroscope clearance K254294
K254294 names the Single-use Digital Hysteroscope across GYUT-A configurations at 12.6 and 14.4 sizes and GYUT-B configurations at size 15, each offered in 0, 12, 22 and 30 variants. The FDA record lists product code HIH, regulation number 884.1690, device class 2, advisory committee Obstetrics/Gynecology, a Traditional clearance type and a decision date of September 8, 2026, with the application received December 31, 2025. The decision is recorded as Substantially Equivalent. [2]
Applicant identity and company-published details
The FDA records identify the applicant as Zhejiang Geyi Medical Instrument Co., Ltd., with a Jiande City, Zhejiang address and Cathy Tan as contact. That filing address is not evidence of a corporate headquarters. The public documents do not identify a parent company, brand owner or affiliated legal entity, so the applicant is treated only as the named 510(k) holder. [1][2][7]
Geyi Medical's own company profile describes a 15-year medical device manufacturer focused on minimally invasive surgery and single-use endoscopy, operating a 26,500 m² facility with a 1,500 m² Class 100,000 cleanroom, a 500 m² laboratory and two in-house sterilization chambers, and states ISO 13485 compliance and MDSAP registration. Its homepage lists single-use cystoscope, hysteroscope, ureteroscope and bronchoscope lines and cites two factories, 200+ employees, 80+ patents, 80+ countries and 60+ distributors. These are company-published claims and were not independently verified in the public documents. [5][8]
Scope of the documented record
The supplied collection contains two linked 510(k) records, both with a Substantially Equivalent decision, and no recall records. The record sample contains the same two entries, so the sample decision count and the collection decision count both show two SESE decisions. These figures describe the supplied filings as of the snapshot date and are not measures of total company sales, total portfolio size or safety performance. [1][2]
An additional FDA letter in the public documents references K252468, dated December 16, 2025, for Single-use Digital Flexible Ureteroscopes GY-UR9.3, GY-UR8.4 and GY-UR7.5 and an Endoscope camera system GY-AIO-121. That letter is not among the linked portfolio records, so it is noted only as a separate document and not counted in the two-record collection. [10]


